Compare · ABT vs ASBP
ABT vs ASBP
Side-by-side comparison of Abbott Laboratories (ABT) and Aspire Biopharma Holdings Inc. (ASBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ASBP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $161.63B, about 131305.9x ASBP ($1.2M).
- Over the past year, ABT is down 28.4% and ASBP is down 98.7% - ABT leads by 70.3 points.
- ASBP has been more active in the news (14 items in the past 4 weeks vs 10 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for ASBP).
- Company
- Abbott Laboratories
- Aspire Biopharma Holdings Inc.
- Price
- $92.82+1.83%
- $0.24+19.94%
- Market cap
- $161.63B
- $1.2M
- 1M return
- -11.26%
- -77.14%
- 1Y return
- -28.37%
- -98.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 14
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- EVP AND CFO Boudreau Philip P bought $201,300 worth of Common shares without par value (2,200 units at $91.50) (SEC Form 4)
- Abbott Laboratories filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
- SEC Form S-8 filed by Abbott Laboratories
- Abbott Labs downgraded by Daiwa Securities with a new price target
- Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
- New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
Latest ASBP
- Aspire Biopharma Announces $5.0 Million Share Repurchase Program
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
- Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
- Amendment: Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
- Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion